Methotrexate therapy in rheumatoid arthritis: 15 years experience☆
References (22)
- et al.
Comparison of azathioprine, cyclophosphamide and gold in treatment of rheumatoid arthritis
Br Med J
(1974) - et al.
Long-term effects of azathioprine in rheumatoid arthritis
Ann Rheum Dis
(1982) Methotrexate in rheumatoid arthritis (abstr)
Arthritis Rheum
(1972)- et al.
Long term therapy of psioriatic and rheumatoid arthritis with oral methotrexate monitored by serial liver biopsies (abstr)
Arthritis Rheum
(1979) - et al.
Low-dose pulse therapy in rheumatoid arthritis
J Rheumatol
(1980) - et al.
Low dose methotrexate therapy in rheumatoid arthritis
Arthritis Rheum
(1981) - et al.
Methotrexate in the treatment of rheumatoid arthritis: pilot study
Clev Clin Q
(1980) - et al.
Methotrexate therapy in psoriatic arthritis
JAMA
(1964) - et al.
Reiter's syndrome. Treatment with methotrexate
JAMA
(1967) - et al.
Pulmonary disease complicating intermittent therapy with methotrexate
JAMA
(1969)
Treatment of rheumatoid arthritis with nitrogen mustard. Preliminary report
JAMA
Cited by (174)
Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review
2018, European Journal of Medicinal ChemistryCitation Excerpt :It has anti-inflammatory and immunomodulating properties [1–4] and used for the treatment of RA and psoriasis in 1951 for the first time [5]. However, until the early 1980s [6,7], MTX therapy started receiving more attention to be used in the treatment of RA. Its high efficacy and marked superiority to placebo in chronic and severe RA patients was then reported a few years later [8,9].
Discoveries of conventional synthetic disease modifying anti-rheumatic drugs - Serendipity or flawless reasoning?
2016, Indian Journal of RheumatologyCitation Excerpt :Hoffmeister also showed that the effect of LD-MTX was similar to that of intramuscular gold and d-penicillamine (the commonly used drugs in those days) with less toxicity and rapid action. Around the same time (early 1980s), Willkens also published his initial series of 67 patients who were treated with LD-MTX at a dose varying from 7.5 to 15 mg per week from 3 months to 10 years.64,65 He also reported an overall improvement in more than 75% of RA patients.
Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort
2015, Seminars in Arthritis and RheumatismCitation Excerpt :Furthermore, gastrointestinal (GI) side effects, such as nausea, abdominal pain, and diarrhea, are a frequent cause of oral MTX therapy discontinuation [3,21]. Guidelines from other European rheumatology societies have also recommended a switch from oral to parenteral MTX as part of the management of RA [22–26]. A retrospective, controlled, population-based, observational study from the United Kingdom assessed the efficacy of SC MTX in patients who had an inadequate response to oral MTX therapy [27].
Treatment of rheumatoid arthritis: Unraveling the conundrum
2015, Journal of AutoimmunityCitation Excerpt :It was soon shown to be effective in RA (and psoriasis and psoriatic arthritis) by Gubner and co-workers in 1951 [33]. Like SSZ, however, it emerged at the dawning of the short-lived first glucocorticoid era, and its use in RA “suffered” until the early 1980s [34,35]. By the 1990s, MTX had become the first drug of choice of most rheumatologists to treat patients with RA, although early efficacy studies suggested that, at least within the first year of use, other drugs, including SSZ, were equally efficacious [36].
Methotrexate in rheumatoid arthritis: Optimizing therapy among different formulations. Current and emerging paradigms
2014, Clinical TherapeuticsCitation Excerpt :Therefore, for almost a decade, immunosuppressive drugs were used as rescue therapy, after repeated failure of all other possible therapeutic options. In 1972, Hoffmeister demonstrated both the availability and safety of MTX, at low doses, with a single weekly administration.4 After publication of this article, this strategy became the first choice in the treatment of RA.
The Methotrexate Story: How did a Cancer Chemotherapeutic Agent Become a Disease-modifying Antirheumatic Drug
2023, Indian Journal of Rheumatology
- ☆
This study was supported in part by the Rockwood Clinic Medical Foundation.
- 1
From the Section of Rheumatology, Department of Medicine, Rockwood Clinic, Spokane, Washington.